Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health
Ursodeoxycholic acid (UDCA) exerts anticholestatic, antifibrotic and antiproliferative effects in primary biliary cirrhosis (PBC) via mechanisms not yet fully understood. Its adequate biliary enrichment is considered mandatory for therapeutic efficacy. However, precise determination of biliary enric...
Saved in:
| Published in | Journal of hepatology Vol. 57; no. 1; pp. 133 - 140 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Kidlington
Elsevier B.V
01.07.2012
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Ursodeoxycholic acid (UDCA) exerts anticholestatic, antifibrotic and antiproliferative effects in primary biliary cirrhosis (PBC) via mechanisms not yet fully understood. Its adequate biliary enrichment is considered mandatory for therapeutic efficacy. However, precise determination of biliary enrichment of UDCA is not possible in clinical practice. Therefore, we investigated (i) the relationship between biliary enrichment and plasma pharmacokinetics of UDCA, (ii) the effect of UDCA on plasma and biliary bile acid composition and conjugation patterns, and (iii) on the intestinal detoxification machinery in patients with PBC and healthy controls.
In 11 PBC patients and 11 matched healthy subjects, cystic bile and duodenal tissue were collected before and after 3weeks of administration of UDCA (15mg/kg/day). Extensive pharmacokinetic profiling of bile acids was performed. The effect of UDCA on the intestinal detoxification machinery was studied by quantitative PCR and Western blotting.
The relative fraction of UDCA and its conjugates in plasma at trough level[x] correlated with their biliary enrichment[y] (r=0.73, p=0.0001, y=3.65+0.49x). Taurine conjugates of the major hydrophobic bile acid, chenodeoxycholic acid, were more prominent in bile of PBC patients than in that of healthy controls. Biliary bile acid conjugation patterns normalized after treatment with UDCA. UDCA induced duodenal expression of key export pumps, BCRP and P-glycoprotein.
Biliary and trough plasma enrichment of UDCA are closely correlated in PBC and health. Taurine conjugation may represent an adaptive mechanism in PBC against chenodeoxycholic acid-mediated bile duct damage. UDCA may stabilize small intestinal detoxification by upregulation of efflux pumps. |
|---|---|
| AbstractList | Ursodeoxycholic acid (UDCA) exerts anticholestatic, antifibrotic and antiproliferative effects in primary biliary cirrhosis (PBC) via mechanisms not yet fully understood. Its adequate biliary enrichment is considered mandatory for therapeutic efficacy. However, precise determination of biliary enrichment of UDCA is not possible in clinical practice. Therefore, we investigated (i) the relationship between biliary enrichment and plasma pharmacokinetics of UDCA, (ii) the effect of UDCA on plasma and biliary bile acid composition and conjugation patterns, and (iii) on the intestinal detoxification machinery in patients with PBC and healthy controls.
In 11 PBC patients and 11 matched healthy subjects, cystic bile and duodenal tissue were collected before and after 3weeks of administration of UDCA (15mg/kg/day). Extensive pharmacokinetic profiling of bile acids was performed. The effect of UDCA on the intestinal detoxification machinery was studied by quantitative PCR and Western blotting.
The relative fraction of UDCA and its conjugates in plasma at trough level[x] correlated with their biliary enrichment[y] (r=0.73, p=0.0001, y=3.65+0.49x). Taurine conjugates of the major hydrophobic bile acid, chenodeoxycholic acid, were more prominent in bile of PBC patients than in that of healthy controls. Biliary bile acid conjugation patterns normalized after treatment with UDCA. UDCA induced duodenal expression of key export pumps, BCRP and P-glycoprotein.
Biliary and trough plasma enrichment of UDCA are closely correlated in PBC and health. Taurine conjugation may represent an adaptive mechanism in PBC against chenodeoxycholic acid-mediated bile duct damage. UDCA may stabilize small intestinal detoxification by upregulation of efflux pumps. Background & Aims Ursodeoxycholic acid (UDCA) exerts anticholestatic, antifibrotic and antiproliferative effects in primary biliary cirrhosis (PBC) via mechanisms not yet fully understood. Its adequate biliary enrichment is considered mandatory for therapeutic efficacy. However, precise determination of biliary enrichment of UDCA is not possible in clinical practice. Therefore, we investigated (i) the relationship between biliary enrichment and plasma pharmacokinetics of UDCA, (ii) the effect of UDCA on plasma and biliary bile acid composition and conjugation patterns, and (iii) on the intestinal detoxification machinery in patients with PBC and healthy controls. Methods In 11 PBC patients and 11 matched healthy subjects, cystic bile and duodenal tissue were collected before and after 3 weeks of administration of UDCA (15 mg/kg/day). Extensive pharmacokinetic profiling of bile acids was performed. The effect of UDCA on the intestinal detoxification machinery was studied by quantitative PCR and Western blotting. Results The relative fraction of UDCA and its conjugates in plasma at trough level[x] correlated with their biliary enrichment[y] (r = 0.73, p = 0.0001, y = 3.65 + 0.49 x ). Taurine conjugates of the major hydrophobic bile acid, chenodeoxycholic acid, were more prominent in bile of PBC patients than in that of healthy controls. Biliary bile acid conjugation patterns normalized after treatment with UDCA. UDCA induced duodenal expression of key export pumps, BCRP and P-glycoprotein. Conclusions Biliary and trough plasma enrichment of UDCA are closely correlated in PBC and health. Taurine conjugation may represent an adaptive mechanism in PBC against chenodeoxycholic acid-mediated bile duct damage. UDCA may stabilize small intestinal detoxification by upregulation of efflux pumps. Ursodeoxycholic acid (UDCA) exerts anticholestatic, antifibrotic and antiproliferative effects in primary biliary cirrhosis (PBC) via mechanisms not yet fully understood. Its adequate biliary enrichment is considered mandatory for therapeutic efficacy. However, precise determination of biliary enrichment of UDCA is not possible in clinical practice. Therefore, we investigated (i) the relationship between biliary enrichment and plasma pharmacokinetics of UDCA, (ii) the effect of UDCA on plasma and biliary bile acid composition and conjugation patterns, and (iii) on the intestinal detoxification machinery in patients with PBC and healthy controls.BACKGROUND & AIMSUrsodeoxycholic acid (UDCA) exerts anticholestatic, antifibrotic and antiproliferative effects in primary biliary cirrhosis (PBC) via mechanisms not yet fully understood. Its adequate biliary enrichment is considered mandatory for therapeutic efficacy. However, precise determination of biliary enrichment of UDCA is not possible in clinical practice. Therefore, we investigated (i) the relationship between biliary enrichment and plasma pharmacokinetics of UDCA, (ii) the effect of UDCA on plasma and biliary bile acid composition and conjugation patterns, and (iii) on the intestinal detoxification machinery in patients with PBC and healthy controls.In 11 PBC patients and 11 matched healthy subjects, cystic bile and duodenal tissue were collected before and after 3 weeks of administration of UDCA (15 mg/kg/day). Extensive pharmacokinetic profiling of bile acids was performed. The effect of UDCA on the intestinal detoxification machinery was studied by quantitative PCR and Western blotting.METHODSIn 11 PBC patients and 11 matched healthy subjects, cystic bile and duodenal tissue were collected before and after 3 weeks of administration of UDCA (15 mg/kg/day). Extensive pharmacokinetic profiling of bile acids was performed. The effect of UDCA on the intestinal detoxification machinery was studied by quantitative PCR and Western blotting.The relative fraction of UDCA and its conjugates in plasma at trough level[x] correlated with their biliary enrichment[y] (r=0.73, p=0.0001, y=3.65+0.49x). Taurine conjugates of the major hydrophobic bile acid, chenodeoxycholic acid, were more prominent in bile of PBC patients than in that of healthy controls. Biliary bile acid conjugation patterns normalized after treatment with UDCA. UDCA induced duodenal expression of key export pumps, BCRP and P-glycoprotein.RESULTSThe relative fraction of UDCA and its conjugates in plasma at trough level[x] correlated with their biliary enrichment[y] (r=0.73, p=0.0001, y=3.65+0.49x). Taurine conjugates of the major hydrophobic bile acid, chenodeoxycholic acid, were more prominent in bile of PBC patients than in that of healthy controls. Biliary bile acid conjugation patterns normalized after treatment with UDCA. UDCA induced duodenal expression of key export pumps, BCRP and P-glycoprotein.Biliary and trough plasma enrichment of UDCA are closely correlated in PBC and health. Taurine conjugation may represent an adaptive mechanism in PBC against chenodeoxycholic acid-mediated bile duct damage. UDCA may stabilize small intestinal detoxification by upregulation of efflux pumps.CONCLUSIONSBiliary and trough plasma enrichment of UDCA are closely correlated in PBC and health. Taurine conjugation may represent an adaptive mechanism in PBC against chenodeoxycholic acid-mediated bile duct damage. UDCA may stabilize small intestinal detoxification by upregulation of efflux pumps. Ursodeoxycholic acid (UDCA) exerts anticholestatic, antifibrotic and antiproliferative effects in primary biliary cirrhosis (PBC) via mechanisms not yet fully understood. Its adequate biliary enrichment is considered mandatory for therapeutic efficacy. However, precise determination of biliary enrichment of UDCA is not possible in clinical practice. Therefore, we investigated (i) the relationship between biliary enrichment and plasma pharmacokinetics of UDCA, (ii) the effect of UDCA on plasma and biliary bile acid composition and conjugation patterns, and (iii) on the intestinal detoxification machinery in patients with PBC and healthy controls. In 11 PBC patients and 11 matched healthy subjects, cystic bile and duodenal tissue were collected before and after 3 weeks of administration of UDCA (15 mg/kg/day). Extensive pharmacokinetic profiling of bile acids was performed. The effect of UDCA on the intestinal detoxification machinery was studied by quantitative PCR and Western blotting. The relative fraction of UDCA and its conjugates in plasma at trough level[x] correlated with their biliary enrichment[y] (r=0.73, p=0.0001, y=3.65+0.49x). Taurine conjugates of the major hydrophobic bile acid, chenodeoxycholic acid, were more prominent in bile of PBC patients than in that of healthy controls. Biliary bile acid conjugation patterns normalized after treatment with UDCA. UDCA induced duodenal expression of key export pumps, BCRP and P-glycoprotein. Biliary and trough plasma enrichment of UDCA are closely correlated in PBC and health. Taurine conjugation may represent an adaptive mechanism in PBC against chenodeoxycholic acid-mediated bile duct damage. UDCA may stabilize small intestinal detoxification by upregulation of efflux pumps. |
| Author | Beuers, Ulrich Dilger, Karin Winkler-Budenhofer, Ursula Hohenester, Simon Schaap, Frank G. Bastiaansen, Barbara A.J. Rust, Christian |
| Author_xml | – sequence: 1 givenname: Karin surname: Dilger fullname: Dilger, Karin organization: Dr. Falk Pharma GmbH, Freiburg, Germany – sequence: 2 givenname: Simon surname: Hohenester fullname: Hohenester, Simon organization: Tytgat Institute for Liver and Intestinal Research, Department of Gastroenterology & Hepatology, Academic Medical Center, Amsterdam, The Netherlands – sequence: 3 givenname: Ursula surname: Winkler-Budenhofer fullname: Winkler-Budenhofer, Ursula organization: Department of Medicine II, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany – sequence: 4 givenname: Barbara A.J. surname: Bastiaansen fullname: Bastiaansen, Barbara A.J. organization: Tytgat Institute for Liver and Intestinal Research, Department of Gastroenterology & Hepatology, Academic Medical Center, Amsterdam, The Netherlands – sequence: 5 givenname: Frank G. surname: Schaap fullname: Schaap, Frank G. organization: Tytgat Institute for Liver and Intestinal Research, Department of Gastroenterology & Hepatology, Academic Medical Center, Amsterdam, The Netherlands – sequence: 6 givenname: Christian surname: Rust fullname: Rust, Christian organization: Department of Medicine II, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany – sequence: 7 givenname: Ulrich surname: Beuers fullname: Beuers, Ulrich email: u.h.beuers@amc.uva.nl organization: Tytgat Institute for Liver and Intestinal Research, Department of Gastroenterology & Hepatology, Academic Medical Center, Amsterdam, The Netherlands |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25986370$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22414767$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk-LFDEQxYOsuLOrX8CD9EXw0mMlnc70iCzIsv6BBQ_qOaSTCl1jprMmPbJz94ObdkaFBVcIJIHfe0nVqzN2MsYRGXvKYcmBq5eb5WbAm6UALpZQFpcP2IIrgBqU5CdsUaCu7sSqO2VnOW8AoIG1fMROhZBcrtRqwX5ceY92qqKvdilHh_F2b4cYyFbGkqviWPUU8HC5SdGXS67M6CoaJ8wTjSZUDqd4S56smagItsYONGLaF6ZoaGvKsbjQvFtKaYiZDiYDmjANj9lDb0LGJ8f9nH15e_X58n19_fHdh8s317Vt226qJSgHaL1R2Ku-haaVYDvj-zXvjVfSdUqhcaC49KppjWysXHnX2b71UnhsztmLg28p5Nuu_F5vKVsMwYwYd1lzEFy03VpAQZ8d0V2_RaePZejfnSvA8yNgsjXBJzNayn-5dt2pZjUbiQNnU8w5of-DcNBzjHqj5xj1HKOGsrgsou6OyNL0q7lTMhTul74-SLE08jth0tkSjhYdpRK0dpHul1_ckdtAY0k2fMU95k3cpZJ4aZXORaA_zSM2TxgXALNPMXj1b4P_vf4Tnn3jDA |
| CODEN | JOHEEC |
| CitedBy_id | crossref_primary_10_1016_j_bfopcu_2014_02_002 crossref_primary_10_1097_HEP_0000000000001225 crossref_primary_10_3892_etm_2016_3977 crossref_primary_10_1111_liv_12368 crossref_primary_10_2967_jnumed_115_161711 crossref_primary_10_1016_j_jaut_2018_05_008 crossref_primary_10_1016_j_jhep_2019_11_018 crossref_primary_10_1016_S2210_7401_12_70016_5 crossref_primary_10_1016_j_phrs_2015_12_007 crossref_primary_10_1096_fba_2018_00046 crossref_primary_10_59717_j_xinn_life_2024_100093 crossref_primary_10_1016_j_cld_2018_03_013 crossref_primary_10_1016_j_bbrc_2014_04_048 crossref_primary_10_1007_s40265_021_01545_7 crossref_primary_10_1186_1471_230X_13_175 crossref_primary_10_26599_FSHW_2024_9250045 crossref_primary_10_1016_j_jceh_2021_08_017 crossref_primary_10_3390_cells8030253 crossref_primary_10_1038_s41575_022_00687_7 crossref_primary_10_1080_19490976_2023_2183690 crossref_primary_10_1016_j_jhep_2017_04_026 crossref_primary_10_4254_wjh_v8_i8_401 crossref_primary_10_1016_j_bpg_2021_101763 crossref_primary_10_1371_journal_pone_0265418 crossref_primary_10_1186_s12934_024_02592_x crossref_primary_10_1080_17474124_2016_1216784 crossref_primary_10_3390_ijms25042194 crossref_primary_10_1007_s00117_019_0513_x crossref_primary_10_1111_liv_13306 crossref_primary_10_1016_j_jhep_2014_05_018 crossref_primary_10_3390_ijms26041759 crossref_primary_10_1016_j_foodres_2018_12_065 crossref_primary_10_3390_cells12050792 crossref_primary_10_1016_j_jaut_2019_102328 crossref_primary_10_1002_psp4_12100 crossref_primary_10_3389_fimmu_2018_01853 crossref_primary_10_1016_j_jhep_2014_12_034 crossref_primary_10_1002_cpdd_24 crossref_primary_10_1016_j_ejphar_2018_01_021 crossref_primary_10_1155_2021_6691425 crossref_primary_10_1007_s11684_012_0227_1 crossref_primary_10_3390_nu13031018 crossref_primary_10_1053_j_gastro_2013_03_018 crossref_primary_10_1186_s41936_020_00197_5 crossref_primary_10_1111_liv_13714 crossref_primary_10_1002_hep_27074 crossref_primary_10_1111_bcpt_12449 crossref_primary_10_1371_journal_pone_0246161 crossref_primary_10_1016_j_lfs_2021_119252 crossref_primary_10_1016_j_biomaterials_2022_121459 crossref_primary_10_1002_jcp_27905 crossref_primary_10_3390_cells10102772 crossref_primary_10_1016_j_fct_2020_111133 crossref_primary_10_1002_ptr_5575 crossref_primary_10_1016_j_bbamem_2013_05_007 crossref_primary_10_1038_s41598_017_15338_0 crossref_primary_10_1248_bpb_b21_00332 crossref_primary_10_1016_j_apjtm_2017_06_003 crossref_primary_10_1080_17425255_2020_1701653 crossref_primary_10_1248_yakushi_20_00156 crossref_primary_10_1159_000371864 crossref_primary_10_3109_03009734_2014_985763 crossref_primary_10_1016_j_jcmgh_2020_02_005 crossref_primary_10_1038_s41598_023_37354_z crossref_primary_10_1155_2024_4187796 crossref_primary_10_1007_s12016_019_08731_2 crossref_primary_10_1080_14787210_2024_2376153 crossref_primary_10_1080_19490976_2019_1674124 crossref_primary_10_3390_cells9020281 crossref_primary_10_1002_hep_29029 crossref_primary_10_1111_liv_15982 crossref_primary_10_3389_fphys_2021_718783 crossref_primary_10_1016_j_jhep_2017_03_022 crossref_primary_10_1016_j_jpeds_2016_05_008 crossref_primary_10_1002_hep_26228 crossref_primary_10_1016_j_jcf_2018_08_009 crossref_primary_10_1016_j_taap_2015_01_015 crossref_primary_10_1038_nrgastro_2015_12 crossref_primary_10_12998_wjcc_v7_i13_1571 crossref_primary_10_3390_ijms19041120 crossref_primary_10_3390_ijms25084321 crossref_primary_10_1002_jcph_1409 crossref_primary_10_1016_j_jhep_2015_02_023 crossref_primary_10_5604_16652681_1198826 crossref_primary_10_1186_s13317_019_0120_x crossref_primary_10_1016_j_jhepr_2021_100255 crossref_primary_10_3390_cells11152344 |
| Cites_doi | 10.1053/gast.2003.50156 10.1038/ajg.2010.216 10.1016/j.clpt.2006.01.005 10.1002/hep.22428 10.1074/jbc.M909992199 10.1016/j.jhep.2010.05.015 10.1111/j.1476-5381.2008.00030.x 10.1016/j.gastro.2005.05.009 10.1016/S0022-3565(24)29314-9 10.2165/00003088-200140030-00002 10.1136/gut.2005.067389 10.1111/j.1365-2036.2005.02650.x 10.1016/j.jhep.2009.04.009 10.1002/hep.1840140609 10.1002/hep.22906 10.1053/j.gastro.2005.12.029 10.1007/s00424-006-0109-y 10.1111/j.1572-0241.1998.00470.x 10.1002/hep.24691 10.1136/gut.13.3.201 10.1016/S1590-8658(02)80112-8 10.1002/hep.20568 10.1053/j.gastro.2009.01.003 10.1074/jbc.M804585200 10.1002/hep.510250104 10.1046/j.1365-2036.1998.00395.x 10.1053/jhep.2002.36088 10.1016/S0168-8278(11)60700-9 10.2174/138920010792927325 10.1002/hep.23810 10.1007/s12016-008-8085-y 10.1016/S0016-5085(99)70564-0 10.1038/ncpgasthep0521 10.1053/jhep.2003.50311 |
| ContentType | Journal Article |
| Copyright | 2012 2015 INIST-CNRS Copyright © 2012. Published by Elsevier B.V. |
| Copyright_xml | – notice: 2012 – notice: 2015 INIST-CNRS – notice: Copyright © 2012. Published by Elsevier B.V. |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.jhep.2012.02.014 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1600-0641 |
| EndPage | 140 |
| ExternalDocumentID | 22414767 25986370 10_1016_j_jhep_2012_02_014 S0168827812002012 1_s2_0_S0168827812002012 |
| Genre | Research Support, Non-U.S. Gov't Controlled Clinical Trial Journal Article |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29K 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 D-I DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDZ HMK HMO HVGLF HX~ HZ~ IHE J1W KOM LZ1 M27 M41 MJL MO0 N9A O-L O9- OAUVE OC. ON0 OVD OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K TEORI UV1 WUQ X7M YOC Z5R ZGI ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR AAYXX AGRNS CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c558t-406d0ecfa6eb6b503540c8afb91baf64d866ead0614f635a43c47fd8cb5f42fe3 |
| IEDL.DBID | .~1 |
| ISSN | 0168-8278 1600-0641 |
| IngestDate | Mon Jul 21 09:46:09 EDT 2025 Mon Jul 21 06:05:54 EDT 2025 Mon Jul 21 09:15:21 EDT 2025 Tue Jul 01 05:13:59 EDT 2025 Thu Apr 24 23:02:38 EDT 2025 Fri Feb 23 02:27:17 EST 2024 Sun Feb 23 10:19:29 EST 2025 Tue Aug 26 20:13:17 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | FXR PTF RXRα TUDCA UDCA MRP PXR GCDCA AE2 PBC SLCA MDR1 Biotransformation AUC0–24h Clinical trial ASBT GDCA CYP CA UGT1A7 SULT2A1 CDCA BCRP Cmax Drug transport GLCA DCA GUDCA GCA ABCC7 VDR TDCA OATP OSTα/OSTβ LCA TCDCA PPARα GlnUDCA TLCA TCA CAR SUDCA Cholestasis Bile cholic acid taurocholic acid anion exchanger 2 retinoid X receptor alpha pregnane X receptor deoxycholic acid AUC 0–24 h multidrug resistance 1 peak-trough-fluctuation tauroursodeoxycholic acid lithocholic acid-3-sulfate primary biliary cirrhosis glycochenodeoxycholic acid vitamin D receptor apical sodium-dependent bile acid transporter area under the plasma concentration-time curve during 24 h breast cancer resistance protein organic solute transporter α/β glycocholic acid lithocholic acid taurolithocholic acid taurochenodeoxycholic acid glycodeoxycholic acid glycolithocholic acid taurodeoxycholic acid organic anion transporting polypeptide C max cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C member 7) multidrug resistance associated protein ursodeoxycholic acid peroxisome proliferator-activated receptor alpha glycoursodeoxycholic acid ursodeoxycholic acid-3-beta-glucuronide peak plasma concentration farnesoid X receptor bile-salt sulfotransferase 2A1 ursodeoxycholic acid-3-sulfate cytochrome P450 constitutive androstane receptor chenodeoxycholic acid UDP-glucuronosyltransferase 1 family polypeptide A7 Primary biliary cirrhosis Detoxification Gut Hepatic disease Biliary tract disease Ursodeoxycholic acid Bile acid Cholostasis Gastroenterology Digestive diseases |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright © 2012. Published by Elsevier B.V. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c558t-406d0ecfa6eb6b503540c8afb91baf64d866ead0614f635a43c47fd8cb5f42fe3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 22414767 |
| PQID | 1021258920 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1021258920 pubmed_primary_22414767 pascalfrancis_primary_25986370 crossref_primary_10_1016_j_jhep_2012_02_014 crossref_citationtrail_10_1016_j_jhep_2012_02_014 elsevier_sciencedirect_doi_10_1016_j_jhep_2012_02_014 elsevier_clinicalkeyesjournals_1_s2_0_S0168827812002012 elsevier_clinicalkey_doi_10_1016_j_jhep_2012_02_014 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-07-01 |
| PublicationDateYYYYMMDD | 2012-07-01 |
| PublicationDate_xml | – month: 07 year: 2012 text: 2012-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington – name: Netherlands |
| PublicationTitle | Journal of hepatology |
| PublicationTitleAlternate | J Hepatol |
| PublicationYear | 2012 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Ni, Bikadi, Rosenberg (b0170) 2010; 11 Batta, Salen, Mirchandani (b0055) 1993; 88 Nies, Keppler (b0180) 2007; 453 Wolf, Rybicki, Lashner (b0075) 2005; 22 (b0005) 2009; 51 Van Hoogstraten, De Smet, Renooij (b0105) 1998; 12 Marschall, Wagner, Zollner (b0095) 2005; 129 Prieto, Garcia, Marti-Climent (b0120) 1999; 117 Hohenester, de Buy Wenniger, Paulusma (b0150) 2012; 55 Pares, Caballeria, Rodes (b0025) 2006; 130 Dilger, Denk, Heeg (b0155) 2005; 41 Kuiper, Hansen, de Vries (b0020) 2009; 136 Lindor, Lacerda, Jorgensen (b0045) 1998; 93 Kumagi, Guindi, Fischer (b0030) 2010; 105 Becquemont, Glaeser, Drescher (b0165) 2006; 79 Beuers, Hohenester, De Buy Wenniger, Kremer, Jansen, Elferink (b0125) 2010; 52 Hohenester, Gates, Wimmer (b0135) 2010; 53 Beuers, Kullak-Ublick, Pusl (b0090) 2009; 36 Beuers (b0035) 2006; 3 Murphy, Ross, Billing (b0110) 1972; 13 Lindor, Gershwin, Poupon (b0010) 2009; 50 Roda, Azzaroli, Nigro (b0060) 2002; 34 Crosignani, Podda, Battezzati (b0050) 1991; 14 Serfaty, De Leusse, Rosmorduc (b0065) 2003; 38 Rust, Karnitz, Paya (b0130) 2000; 275 Rust, Wild, Bernt (b0140) 2009; 284 Paumgartner, Beuers (b0040) 2002; 36 Taipalensuu, Törnblom, Lindberg (b0175) 2001; 299 . Pardi, Loftus, Kremers (b0070) 2003; 124 Corpechot, Abenavoli, Rabahi (b0015) 2008; 48 Hruz, Zimmermann, Gutmann (b0080) 2006; 55 Guidance for Industry. Bioanalytical method validation. Food and Drug Administration. Available from Medina, Martinez, Vazquez (b0115) 1997; 25 Zhang, Benet (b0160) 2001; 40 Zollner, Trauner (b0085) 2009; 156 Schulz, Wimmer, Zischka (b0145) 2011; 54 Hruz (10.1016/j.jhep.2012.02.014_b0080) 2006; 55 Wolf (10.1016/j.jhep.2012.02.014_b0075) 2005; 22 Kumagi (10.1016/j.jhep.2012.02.014_b0030) 2010; 105 Pardi (10.1016/j.jhep.2012.02.014_b0070) 2003; 124 Batta (10.1016/j.jhep.2012.02.014_b0055) 1993; 88 (10.1016/j.jhep.2012.02.014_b0005) 2009; 51 Beuers (10.1016/j.jhep.2012.02.014_b0090) 2009; 36 Marschall (10.1016/j.jhep.2012.02.014_b0095) 2005; 129 Prieto (10.1016/j.jhep.2012.02.014_b0120) 1999; 117 Medina (10.1016/j.jhep.2012.02.014_b0115) 1997; 25 Roda (10.1016/j.jhep.2012.02.014_b0060) 2002; 34 Schulz (10.1016/j.jhep.2012.02.014_b0145) 2011; 54 Beuers (10.1016/j.jhep.2012.02.014_b0125) 2010; 52 Rust (10.1016/j.jhep.2012.02.014_b0130) 2000; 275 Zhang (10.1016/j.jhep.2012.02.014_b0160) 2001; 40 Van Hoogstraten (10.1016/j.jhep.2012.02.014_b0105) 1998; 12 Dilger (10.1016/j.jhep.2012.02.014_b0155) 2005; 41 Beuers (10.1016/j.jhep.2012.02.014_b0035) 2006; 3 Crosignani (10.1016/j.jhep.2012.02.014_b0050) 1991; 14 Pares (10.1016/j.jhep.2012.02.014_b0025) 2006; 130 Ni (10.1016/j.jhep.2012.02.014_b0170) 2010; 11 Paumgartner (10.1016/j.jhep.2012.02.014_b0040) 2002; 36 Murphy (10.1016/j.jhep.2012.02.014_b0110) 1972; 13 Kuiper (10.1016/j.jhep.2012.02.014_b0020) 2009; 136 Corpechot (10.1016/j.jhep.2012.02.014_b0015) 2008; 48 Nies (10.1016/j.jhep.2012.02.014_b0180) 2007; 453 Becquemont (10.1016/j.jhep.2012.02.014_b0165) 2006; 79 Rust (10.1016/j.jhep.2012.02.014_b0140) 2009; 284 Hohenester (10.1016/j.jhep.2012.02.014_b0150) 2012; 55 10.1016/j.jhep.2012.02.014_b0100 Lindor (10.1016/j.jhep.2012.02.014_b0045) 1998; 93 Zollner (10.1016/j.jhep.2012.02.014_b0085) 2009; 156 Serfaty (10.1016/j.jhep.2012.02.014_b0065) 2003; 38 Hohenester (10.1016/j.jhep.2012.02.014_b0135) 2010; 53 Taipalensuu (10.1016/j.jhep.2012.02.014_b0175) 2001; 299 Lindor (10.1016/j.jhep.2012.02.014_b0010) 2009; 50 J Hepatol. 2014 Mar;60(3):684 |
| References_xml | – volume: 36 start-page: 52 year: 2009 end-page: 61 ident: b0090 article-title: Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-) transcriptional modulators? publication-title: Clin Rev Allergy Immunol – reference: Guidance for Industry. Bioanalytical method validation. Food and Drug Administration. Available from: – volume: 40 start-page: 159 year: 2001 end-page: 168 ident: b0160 article-title: The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein publication-title: Clin Pharmacokinet – volume: 299 start-page: 164 year: 2001 end-page: 170 ident: b0175 article-title: Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers publication-title: J Pharmacol Exp Ther – volume: 156 start-page: 7 year: 2009 end-page: 27 ident: b0085 article-title: Nuclear receptors as therapeutic targets in cholestatic liver diseases publication-title: Br J Pharmacol – volume: 11 start-page: 603 year: 2010 end-page: 617 ident: b0170 article-title: Structure and function of the human breast cancer resistance protein (BCRP/ABCG2) publication-title: Curr Drug Metab – volume: 129 start-page: 476 year: 2005 end-page: 485 ident: b0095 article-title: Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans publication-title: Gastroenterology – volume: 136 start-page: 1281 year: 2009 end-page: 1287 ident: b0020 article-title: Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid publication-title: Gastroenterology – volume: 12 start-page: 965 year: 1998 end-page: 971 ident: b0105 article-title: A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 publication-title: Aliment Pharmacol Ther – volume: 55 start-page: 395 year: 2006 end-page: 402 ident: b0080 article-title: Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis publication-title: Gut – volume: 117 start-page: 167 year: 1999 end-page: 172 ident: b0120 article-title: Assessment of biliary bicarbonate secretion in humans by positron emission tomography publication-title: Gastroenterology – volume: 41 start-page: 595 year: 2005 end-page: 602 ident: b0155 article-title: No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis publication-title: Hepatology – volume: 124 start-page: 889 year: 2003 end-page: 893 ident: b0070 article-title: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis publication-title: Gastroenterology – volume: 130 start-page: 715 year: 2006 end-page: 720 ident: b0025 article-title: Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid publication-title: Gastroenterology – volume: 13 start-page: 201 year: 1972 end-page: 206 ident: b0110 article-title: Serum bile acids in primary biliary cirrhosis publication-title: Gut – volume: 52 start-page: 1489 year: 2010 end-page: 1496 ident: b0125 article-title: The biliary HCO(3)(−) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies publication-title: Hepatology – volume: 36 start-page: 525 year: 2002 end-page: 531 ident: b0040 article-title: Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited publication-title: Hepatology – volume: 88 start-page: 691 year: 1993 end-page: 700 ident: b0055 article-title: Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis publication-title: Am J Gastroenterol – volume: 48 start-page: 871 year: 2008 end-page: 877 ident: b0015 article-title: Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis publication-title: Hepatology – volume: 14 start-page: 1000 year: 1991 end-page: 1007 ident: b0050 article-title: Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration publication-title: Hepatology – volume: 55 start-page: 173 year: 2012 end-page: 183 ident: b0150 article-title: A biliary HCO(3)(−) umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes publication-title: Hepatology – volume: 22 start-page: 783 year: 2005 end-page: 788 ident: b0075 article-title: The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis publication-title: Aliment Pharmacol Ther – volume: 54 start-page: S280 year: 2011 ident: b0145 article-title: Differential induction of mitochondrial failure by bile acids in a direct and Ca-independent fashion [abstract] publication-title: J Hepatol – volume: 275 start-page: 20210 year: 2000 end-page: 20216 ident: b0130 article-title: The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade publication-title: J Biol Chem – volume: 79 start-page: 449 year: 2006 end-page: 460 ident: b0165 article-title: Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans publication-title: Clin Pharmacol Ther – volume: 51 start-page: 237 year: 2009 end-page: 267 ident: b0005 article-title: Management of cholestatic liver diseases publication-title: J Hepatol – volume: 50 start-page: 291 year: 2009 end-page: 308 ident: b0010 article-title: Primary biliary cirrhosis publication-title: Hepatology – volume: 38 start-page: 203 year: 2003 end-page: 209 ident: b0065 article-title: Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study publication-title: Hepatology – volume: 25 start-page: 12 year: 1997 end-page: 17 ident: b0115 article-title: Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis publication-title: Hepatology – volume: 105 start-page: 2186 year: 2010 end-page: 2194 ident: b0030 article-title: Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis publication-title: Am J Gastroenterol – volume: 3 start-page: 318 year: 2006 end-page: 328 ident: b0035 article-title: Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis publication-title: Nat Clin Pract Gastroenterol Hepatol – reference: . – volume: 453 start-page: 643 year: 2007 end-page: 659 ident: b0180 article-title: The apical conjugate efflux pump ABCC2 (MRP2) publication-title: Pflugers Arch – volume: 53 start-page: 918 year: 2010 end-page: 926 ident: b0135 article-title: Phosphatidylinositol-3-kinase p110gamma contributes to bile salt-induced apoptosis in primary rat hepatocytes and human hepatoma cells publication-title: J Hepatol – volume: 93 start-page: 1498 year: 1998 end-page: 1504 ident: b0045 article-title: Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis publication-title: Am J Gastroenterol – volume: 34 start-page: 523 year: 2002 end-page: 527 ident: b0060 article-title: Improved liver test and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis publication-title: Dig Liver Dis – volume: 284 start-page: 2908 year: 2009 end-page: 2916 ident: b0140 article-title: Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent publication-title: J Biol Chem – volume: 124 start-page: 889 year: 2003 ident: 10.1016/j.jhep.2012.02.014_b0070 article-title: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis publication-title: Gastroenterology doi: 10.1053/gast.2003.50156 – volume: 105 start-page: 2186 year: 2010 ident: 10.1016/j.jhep.2012.02.014_b0030 article-title: Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis publication-title: Am J Gastroenterol doi: 10.1038/ajg.2010.216 – volume: 79 start-page: 449 year: 2006 ident: 10.1016/j.jhep.2012.02.014_b0165 article-title: Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2006.01.005 – volume: 48 start-page: 871 year: 2008 ident: 10.1016/j.jhep.2012.02.014_b0015 article-title: Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis publication-title: Hepatology doi: 10.1002/hep.22428 – volume: 275 start-page: 20210 year: 2000 ident: 10.1016/j.jhep.2012.02.014_b0130 article-title: The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade publication-title: J Biol Chem doi: 10.1074/jbc.M909992199 – volume: 53 start-page: 918 year: 2010 ident: 10.1016/j.jhep.2012.02.014_b0135 article-title: Phosphatidylinositol-3-kinase p110gamma contributes to bile salt-induced apoptosis in primary rat hepatocytes and human hepatoma cells publication-title: J Hepatol doi: 10.1016/j.jhep.2010.05.015 – volume: 156 start-page: 7 year: 2009 ident: 10.1016/j.jhep.2012.02.014_b0085 article-title: Nuclear receptors as therapeutic targets in cholestatic liver diseases publication-title: Br J Pharmacol doi: 10.1111/j.1476-5381.2008.00030.x – volume: 88 start-page: 691 year: 1993 ident: 10.1016/j.jhep.2012.02.014_b0055 article-title: Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis publication-title: Am J Gastroenterol – volume: 129 start-page: 476 year: 2005 ident: 10.1016/j.jhep.2012.02.014_b0095 article-title: Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans publication-title: Gastroenterology doi: 10.1016/j.gastro.2005.05.009 – ident: 10.1016/j.jhep.2012.02.014_b0100 – volume: 299 start-page: 164 year: 2001 ident: 10.1016/j.jhep.2012.02.014_b0175 article-title: Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(24)29314-9 – volume: 40 start-page: 159 year: 2001 ident: 10.1016/j.jhep.2012.02.014_b0160 article-title: The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200140030-00002 – volume: 55 start-page: 395 year: 2006 ident: 10.1016/j.jhep.2012.02.014_b0080 article-title: Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis publication-title: Gut doi: 10.1136/gut.2005.067389 – volume: 22 start-page: 783 year: 2005 ident: 10.1016/j.jhep.2012.02.014_b0075 article-title: The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2005.02650.x – volume: 51 start-page: 237 year: 2009 ident: 10.1016/j.jhep.2012.02.014_b0005 article-title: Management of cholestatic liver diseases publication-title: J Hepatol doi: 10.1016/j.jhep.2009.04.009 – volume: 14 start-page: 1000 year: 1991 ident: 10.1016/j.jhep.2012.02.014_b0050 article-title: Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration publication-title: Hepatology doi: 10.1002/hep.1840140609 – volume: 50 start-page: 291 year: 2009 ident: 10.1016/j.jhep.2012.02.014_b0010 article-title: Primary biliary cirrhosis publication-title: Hepatology doi: 10.1002/hep.22906 – volume: 130 start-page: 715 year: 2006 ident: 10.1016/j.jhep.2012.02.014_b0025 article-title: Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid publication-title: Gastroenterology doi: 10.1053/j.gastro.2005.12.029 – volume: 453 start-page: 643 year: 2007 ident: 10.1016/j.jhep.2012.02.014_b0180 article-title: The apical conjugate efflux pump ABCC2 (MRP2) publication-title: Pflugers Arch doi: 10.1007/s00424-006-0109-y – volume: 93 start-page: 1498 year: 1998 ident: 10.1016/j.jhep.2012.02.014_b0045 article-title: Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.1998.00470.x – volume: 55 start-page: 173 year: 2012 ident: 10.1016/j.jhep.2012.02.014_b0150 article-title: A biliary HCO(3)(−) umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes publication-title: Hepatology doi: 10.1002/hep.24691 – volume: 13 start-page: 201 year: 1972 ident: 10.1016/j.jhep.2012.02.014_b0110 article-title: Serum bile acids in primary biliary cirrhosis publication-title: Gut doi: 10.1136/gut.13.3.201 – volume: 34 start-page: 523 year: 2002 ident: 10.1016/j.jhep.2012.02.014_b0060 article-title: Improved liver test and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis publication-title: Dig Liver Dis doi: 10.1016/S1590-8658(02)80112-8 – volume: 41 start-page: 595 year: 2005 ident: 10.1016/j.jhep.2012.02.014_b0155 article-title: No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis publication-title: Hepatology doi: 10.1002/hep.20568 – volume: 136 start-page: 1281 year: 2009 ident: 10.1016/j.jhep.2012.02.014_b0020 article-title: Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid publication-title: Gastroenterology doi: 10.1053/j.gastro.2009.01.003 – volume: 284 start-page: 2908 year: 2009 ident: 10.1016/j.jhep.2012.02.014_b0140 article-title: Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent publication-title: J Biol Chem doi: 10.1074/jbc.M804585200 – volume: 25 start-page: 12 year: 1997 ident: 10.1016/j.jhep.2012.02.014_b0115 article-title: Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis publication-title: Hepatology doi: 10.1002/hep.510250104 – volume: 12 start-page: 965 year: 1998 ident: 10.1016/j.jhep.2012.02.014_b0105 article-title: A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10mg/kg or 20mg/kg. Dutch Multicentre PBC Study Group publication-title: Aliment Pharmacol Ther doi: 10.1046/j.1365-2036.1998.00395.x – volume: 36 start-page: 525 year: 2002 ident: 10.1016/j.jhep.2012.02.014_b0040 article-title: Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited publication-title: Hepatology doi: 10.1053/jhep.2002.36088 – volume: 54 start-page: S280 year: 2011 ident: 10.1016/j.jhep.2012.02.014_b0145 article-title: Differential induction of mitochondrial failure by bile acids in a direct and Ca-independent fashion [abstract] publication-title: J Hepatol doi: 10.1016/S0168-8278(11)60700-9 – volume: 11 start-page: 603 year: 2010 ident: 10.1016/j.jhep.2012.02.014_b0170 article-title: Structure and function of the human breast cancer resistance protein (BCRP/ABCG2) publication-title: Curr Drug Metab doi: 10.2174/138920010792927325 – volume: 52 start-page: 1489 year: 2010 ident: 10.1016/j.jhep.2012.02.014_b0125 article-title: The biliary HCO(3)(−) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies publication-title: Hepatology doi: 10.1002/hep.23810 – volume: 36 start-page: 52 year: 2009 ident: 10.1016/j.jhep.2012.02.014_b0090 article-title: Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-) transcriptional modulators? publication-title: Clin Rev Allergy Immunol doi: 10.1007/s12016-008-8085-y – volume: 117 start-page: 167 year: 1999 ident: 10.1016/j.jhep.2012.02.014_b0120 article-title: Assessment of biliary bicarbonate secretion in humans by positron emission tomography publication-title: Gastroenterology doi: 10.1016/S0016-5085(99)70564-0 – volume: 3 start-page: 318 year: 2006 ident: 10.1016/j.jhep.2012.02.014_b0035 article-title: Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis publication-title: Nat Clin Pract Gastroenterol Hepatol doi: 10.1038/ncpgasthep0521 – volume: 38 start-page: 203 year: 2003 ident: 10.1016/j.jhep.2012.02.014_b0065 article-title: Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study publication-title: Hepatology doi: 10.1053/jhep.2003.50311 – reference: - J Hepatol. 2014 Mar;60(3):684 |
| SSID | ssj0003094 |
| Score | 2.3918815 |
| Snippet | Ursodeoxycholic acid (UDCA) exerts anticholestatic, antifibrotic and antiproliferative effects in primary biliary cirrhosis (PBC) via mechanisms not yet fully... Background & Aims Ursodeoxycholic acid (UDCA) exerts anticholestatic, antifibrotic and antiproliferative effects in primary biliary cirrhosis (PBC) via... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 133 |
| SubjectTerms | Adult Bile Bile Acids and Salts - blood Biliary Tract - drug effects Biliary Tract - metabolism Biological and medical sciences Biotransformation Carrier Proteins - genetics Carrier Proteins - metabolism Cholagogues and Choleretics - administration & dosage Cholagogues and Choleretics - blood Cholagogues and Choleretics - pharmacokinetics Cholestasis Cholestasis - drug therapy Cholestasis - metabolism Clinical trial Cytochrome P-450 CYP3A - genetics Cytochrome P-450 CYP3A - metabolism Drug transport Duodenum - drug effects Duodenum - metabolism Female Gastroenterology and Hepatology Gastroenterology. Liver. Pancreas. Abdomen Gene Expression Profiling Glycine - blood Humans Inactivation, Metabolic - physiology Intestinal Mucosa - metabolism Liver Cirrhosis, Biliary - drug therapy Liver Cirrhosis, Biliary - metabolism Liver. Biliary tract. Portal circulation. Exocrine pancreas Medical sciences Middle Aged Other diseases. Semiology Taurine - blood Ursodeoxycholic Acid - administration & dosage Ursodeoxycholic Acid - blood Ursodeoxycholic Acid - pharmacokinetics |
| Title | Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0168827812002012 https://www.clinicalkey.es/playcontent/1-s2.0-S0168827812002012 https://dx.doi.org/10.1016/j.jhep.2012.02.014 https://www.ncbi.nlm.nih.gov/pubmed/22414767 https://www.proquest.com/docview/1021258920 |
| Volume | 57 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBelgzIYY-u-so-gwt6GF9uSLeexhJW0a8vYVuib0Cd12ewSJ9C97Gl_-O4sOaWsHzAwGIc7Rdad7n6ST3eEvAfMynHZkSjrbYIAPqmshTWPSoUWGgCtxa2Bo-NyfsIPTovTDTIbzsJgWGW0_cGm99Y6_jKJozm5qOvJNwArAA8FeCjEPH2lYc4FavnH31dhHiydxvzeVYLU8eBMiPE6P3OYsxL3A-HK-G3O6dGF6mDIfKh1cTsY7Z3S3hPyOKJJuhs6_JRsuGabbB3F7-XPyJ-QnJi2nq4AWVvXXvb2rjZUmdrStqEazEJ4iOW7O6oaSzGNBMx-bN26ZXuJEUW9EOnPPvzSLX4BDfD0ySqwlRrvpl4sztquDo2EQ5bPycnep--zeRLrLiSmKKolSKy0qTNelU6Xukhxa8hUyutpppUvua3KEhQQ15Ie8IrizHDhbWV04XnuHXtBNpu2ca8IZQBgRJ4CR8640bzKMgduOTMMgJVN2Yhkw4BLE5OSY22MH3KIPjuXKCSJQpIpXBkfkQ9rnviWd1KzQY5yOGwK5lGCx7iTS9zE5bo4wzuZyQ4o5T9aOCLFmvOaIt_7j-NrSrZ-tRwz6DORjsjOoHUSTAB-11GNa1fQFUzTX1TTHGheBnW84gaEBpNCvP7Pbr0hD_EpBCi_JZvLxcq9Axi21ON-no3Jg93Z18MveN__PD_-CyF6M5s |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBclhW0wyr6Xbu002NswsS3Zch5LWUnXJi9roW9Cn9Rls0ucQPe-P3x3lpxR1nYwMBjbOlnWne9-kk53hHwCzMpx2JEo622CAD6prIUxj0qFFhoArcWpgfminJ3zrxfFxRY5HPbCoFtl1P1Bp_faOt6ZxN6cXNf15BuAFYCHAiwUYh7MNLyN0amKEdk-OD6ZLTYKmaXTGOK7SpAg7p0Jbl5Xlw7DVuKUIBwZv88-Pb1WHfSaD-ku7sejvV06ekZ2IqCkB6HNz8mWa16QR_O4ZP6S_ArxiWnr6RrAtXXtTa_yakOVqS1tG6pBM4SLmMG7o6qxFCNJgALA2q1btTfoVNTzkf7oPTDd8ieUAZo-XgXWUuPZ1MvlZdvVoZKwz_IVOT_6cnY4S2LqhcQURbUCppU2dcar0ulSFynODplKeT3NtPIlt1VZggzicNIDZFGcGS68rYwuPM-9Y6_JqGkb95ZQBhhG5ClQ5Iwbzassc2CZM8MAW9mUjUk2dLg0MS45psf4LgcHtCuJTJLIJJnCkfEx-byhiV_5YGk28FEO-01BQ0owGg9SibuoXBd_8k5msoOS8i9BHJNiQ3lLlv_5xv1bQrb5tByD6DORjsnHQeokaAFc2lGNa9fQFIzUX1TTHMq8CeL4hxpAGhel2P3PZn0gj2dn81N5erw4eUee4JPgr_yejFbLtdsDVLbS-_Gv-w3qCTS3 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+ursodeoxycholic+acid+on+bile+acid+profiles+and+intestinal+detoxification+machinery+in+primary+biliary+cirrhosis+and+health&rft.jtitle=Journal+of+hepatology&rft.au=Dilger%2C+Karin&rft.au=Hohenester%2C+Simon&rft.au=Winkler-Budenhofer%2C+Ursula&rft.au=Bastiaansen%2C+Barbara+A.J.&rft.date=2012-07-01&rft.issn=0168-8278&rft.volume=57&rft.issue=1&rft.spage=133&rft.epage=140&rft_id=info:doi/10.1016%2Fj.jhep.2012.02.014&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_jhep_2012_02_014 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01688278%2FS0168827812X00072%2Fcov150h.gif |